322 related articles for article (PubMed ID: 7903454)
1. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.
Johansson I; Lundqvist E; Bertilsson L; Dahl ML; Sjöqvist F; Ingelman-Sundberg M
Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11825-9. PubMed ID: 7903454
[TBL] [Abstract][Full Text] [Related]
2. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.
Dahl ML; Johansson I; Bertilsson L; Ingelman-Sundberg M; Sjöqvist F
J Pharmacol Exp Ther; 1995 Jul; 274(1):516-20. PubMed ID: 7616439
[TBL] [Abstract][Full Text] [Related]
3. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.
Aklillu E; Persson I; Bertilsson L; Johansson I; Rodrigues F; Ingelman-Sundberg M
J Pharmacol Exp Ther; 1996 Jul; 278(1):441-6. PubMed ID: 8764380
[TBL] [Abstract][Full Text] [Related]
4. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.
Johansson I; Oscarson M; Yue QY; Bertilsson L; Sjöqvist F; Ingelman-Sundberg M
Mol Pharmacol; 1994 Sep; 46(3):452-9. PubMed ID: 7935325
[TBL] [Abstract][Full Text] [Related]
5. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology.
Steen VM; Andreassen OA; Daly AK; Tefre T; Børresen AL; Idle JR; Gulbrandsen AK
Pharmacogenetics; 1995 Aug; 5(4):215-23. PubMed ID: 8528268
[TBL] [Abstract][Full Text] [Related]
6. Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects.
Dahl ML; Yue QY; Roh HK; Johansson I; Säwe J; Sjöqvist F; Bertilsson L
Pharmacogenetics; 1995 Jun; 5(3):159-64. PubMed ID: 7550367
[TBL] [Abstract][Full Text] [Related]
7. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
Broly F; Meyer UA
Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6.
Wang SL; Huang JD; Lai MD; Liu BH; Lai ML
Clin Pharmacol Ther; 1993 Apr; 53(4):410-8. PubMed ID: 8097442
[TBL] [Abstract][Full Text] [Related]
9. Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes.
Bertilsson L; Meese CO; Yue QY; Dahl ML; Ingelman-Sundberg M; Johansson I; Säwe J; Eichelbaum M
Pharmacogenetics; 1993 Apr; 3(2):94-100. PubMed ID: 8100167
[TBL] [Abstract][Full Text] [Related]
10. Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes.
Daly AK; Armstrong M; Monkman SC; Idle ME; Idle JR
Pharmacogenetics; 1991 Oct; 1(1):33-41. PubMed ID: 1688241
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population.
Dahl ML; Johansson I; Palmertz MP; Ingelman-Sundberg M; Sjöqvist F
Clin Pharmacol Ther; 1992 Jan; 51(1):12-7. PubMed ID: 1346258
[TBL] [Abstract][Full Text] [Related]
12. An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis.
Broly F; Marez D; Sabbagh N; Legrand M; Millecamps S; Lo Guidice JM; Boone P; Meyer UA
Pharmacogenetics; 1995 Dec; 5(6):373-84. PubMed ID: 8747409
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population.
Agúndez JA; Ledesma MC; Ladero JM; Benítez J
Clin Pharmacol Ther; 1995 Mar; 57(3):265-9. PubMed ID: 7697944
[TBL] [Abstract][Full Text] [Related]
14. Genetic basis for differences in debrisoquin polymorphism between a Spanish and other white populations.
Agúndez JA; Martínez C; Ledesma MC; Ladona MG; Ladero JM; Benítez J
Clin Pharmacol Ther; 1994 Apr; 55(4):412-7. PubMed ID: 7909282
[TBL] [Abstract][Full Text] [Related]
15. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.
Broly F; Gaedigk A; Heim M; Eichelbaum M; Morike K; Meyer UA
DNA Cell Biol; 1991 Oct; 10(8):545-58. PubMed ID: 1681816
[TBL] [Abstract][Full Text] [Related]
16. DNA haplotype dependency of debrisoquine 4-hydroxylase (CYP2D6) expression among extensive metabolisers.
Mura C; Panserat S; Vincent-Viry M; Galteau MM; Jacqz-Aigrain E; Krishnamoorthy R
Hum Genet; 1993 Oct; 92(4):367-72. PubMed ID: 7901140
[TBL] [Abstract][Full Text] [Related]
17. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity.
Romkes-Sparks M; Mnuskin A; Chern HD; Persad R; Fleming C; Sibley GN; Smith P; Wilkinson GR; Branch RA
Carcinogenesis; 1994 Sep; 15(9):1955-61. PubMed ID: 7923590
[TBL] [Abstract][Full Text] [Related]
18. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes.
Kagimoto M; Heim M; Kagimoto K; Zeugin T; Meyer UA
J Biol Chem; 1990 Oct; 265(28):17209-14. PubMed ID: 2211621
[TBL] [Abstract][Full Text] [Related]
19. PCR-based CYP2D6 genotyping for Finnish lung cancer patients.
Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Pelkonen O; Vainio H
Pharmacogenetics; 1993 Feb; 3(1):19-27. PubMed ID: 8097947
[TBL] [Abstract][Full Text] [Related]
20. Interpretation of a simple PCR analysis of the CYP2D6(A) and CYP2D6(B) null alleles associated with the debrisoquine/sparteine genetic polymorphism.
Douglas AM; Atchison BA; Somogyi AA; Drummer OH
Pharmacogenetics; 1994 Jun; 4(3):154-8. PubMed ID: 7920695
[No Abstract] [Full Text] [Related]
[Next] [New Search]
